Article
18 Dec 2025
European Biosimilar Updates – Six Denosumab Launches And Positive Opinion For Samsung Bioepis's BYOOVIZ
AUTHORS CONTENT
Article
19 Nov 2025
New FDA Guidance Aims To Simplify The Biosimilar Approval Process
Article
13 Nov 2025
Amgen Files BPCIA Complaints Against Dr. Reddy's/Alvotech And Amneal Regarding Denosumab Biosimilars
Article
09 Oct 2025
Biogen Ordered To Pay Genentech $88.3 Million In Past Royalties On Cabilly Patents
Article
08 Oct 2025
Court Denies Amgen Motion To Dismiss In Etanercept Antitrust Case
Article
08 Oct 2025
PTAB Issues Four IPR Written Decisions In Merck And Johns Hopkins Pembrolizumab Dispute
Article
08 Oct 2025
Amgen And Samsung Bioepis Settle Denosumab BPCIA Case
Article
26 Sep 2025
Amgen Fires Back With Counterclaims In Aflibercept BPCIA Litigation
Article
22 Sep 2025
Alvotech Files PGR Against Regeneron High-Dose Aflibercept Patent
Article
04 Sep 2025
European Biosimilar Updates – Alvotech/Advanz's MYNZEPLI Approval And Bio-Thera/STADA Tocilizumab Alliance
Article
01 Aug 2025
Harrow Enters Agreement To Commercialize Samsung Bioepis's Ophthalmology Biosimilars Following Biogen's Exit
Article
01 Aug 2025
Bio-Thera Announces Acceptance Of BLA For BAT2506 Referencing Johnson & Johnson's SIMPONI® (Golimumab)
Article
30 Jul 2025
Amgen And Accord BioPharma Settle Denosumab BPCIA Case
Article
25 Jun 2025
Teva And Fosun Partner To Develop A Novel Immunotherapy Targeting Melanoma And Other Cancers
Article
22 May 2025
Regeneron Awarded $407 Million In Amgen Antitrust Suit
Article
24 Apr 2025
FDA Approves Biocon Biologics' Bevacizumab Biosimilar
Article
21 Apr 2025
FDA To Phase Out Animal Testing For Monoclonal Antibodies And Other Drugs
Article
15 Apr 2025
Teva And Samsung Bioepis Announce U.S. Launch Of EPYSQLI® (Eculizumab-aagh), A SOLIRIS® Biosimilar
Article
11 Mar 2025
Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 And Anti-CTLA-4 Antibody Combination Method Of Treatment Patents
Article
31 Jan 2025
Amgen And Celltrion Settle Denosumab BPCIA Case